Ernexa Therapeutics Inc. Federal Income Tax Expense (Benefit), Continuing Operations
Ernexa Therapeutics Inc. (ERNA) reported Federal Income Tax Expense (Benefit), Continuing Operations of $21.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-19.
Discontinued › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2020-03-19
- Ernexa Therapeutics Inc. federal income tax expense (benefit), continuing operations for fiscal 2018 was $21.00K.
- Ernexa Therapeutics Inc. federal income tax expense (benefit), continuing operations for fiscal 2014 was $0.00.
- Ernexa Therapeutics Inc. federal income tax expense (benefit), continuing operations for fiscal 2013 was $0.00.
- Ernexa Therapeutics Inc. federal income tax expense (benefit), continuing operations for fiscal 2012 was $0.00.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2018-12-31 | $21.00K 10-K · filed 2020-03-19 |
| 2014-12-31 | $0.00 10-K · filed 2015-03-27 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-27 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |